Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bbfa9259161eaad1e2030258af18f3d55> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bbfa9259161eaad1e2030258af18f3d55 NCIT_P378 "NCI" @default.
- Bbfa9259161eaad1e2030258af18f3d55 type Axiom @default.
- Bbfa9259161eaad1e2030258af18f3d55 annotatedProperty IAO_0000115 @default.
- Bbfa9259161eaad1e2030258af18f3d55 annotatedSource NCIT_C102564 @default.
- Bbfa9259161eaad1e2030258af18f3d55 annotatedTarget "A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers." @default.